News

Cardio Diagnostics, Inc. has pioneered a proprietary artificial intelligence-driven Integrated Genetic-Epigenetic Engine™ that enables improved diagnosis and prevention of cardiovascular disease The Company’s flagship product, Epi+Gen CHD™, is a highly sensitive and...

Pioneer of AI-driven, epigenetics-based clinical tests for cardiovascular disease moves for Chicago's thriving biotech ecosystem and access to talent and resources CHICAGO, May 25, 2022 – Cardio Diagnostics, Inc., ("Cardio Diagnostics"), a company pioneering...

Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough  Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry CHICAGO, October 27, 2021 – Cardio Diagnostics, Inc., a...

Cardio Diagnostics’ Epi+Gen CHD at-home sampling kit: Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to their home. After the sample is collected, it is shipped...

Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.

Cardio Diagnostics won the Biotech Innovation Showcase Award and received a $5,000 grand prize at the annual IowaBio Partnering for Growth Conference.